Lepu Biopharma Co., Ltd announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc. (Nasdaq: AVBP) for MRG007, a Potential Best-in-Class antibody- drug conjugate (“ADC”) for the treatment of Gastrointestinal (“GI”) Cancers.

乐普生物制药有限公司宣布，已与ArriVent Biopharma，Inc.（纳斯达克：AVBP）就MRG007达成独家许可协议，MRG007是一种潜在的同类最佳抗体-药物偶联物（“ADC”），用于治疗胃肠道（“GI”）癌症。

Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan. Lepu Biopharma will receive a one-time upfront and near-term milestone payments totaling $47 million in cash and is eligible to receive up to $1.16 billion in development, regulatory and sales milestones and tiered royalties on net sales outside of Greater China..

根据协议条款，乐普生物制药已授予ArriVent在大中华地区（包括中国大陆、香港、澳门和台湾）以外开发、制造和商业化MRG007的专有权。。。

MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The first IND submission is planned for the first half of 2025 with an initial clinical development focus in colorectal, pancreatic and other GI cancers.

MRG007在胃肠道癌症的临床前模型中显示出强大的抗肿瘤活性，并且基于IND使能研究显示出有利的治疗指数。第一次IND提交计划于2025年上半年提交，最初的临床开发重点是结直肠癌，胰腺癌和其他胃肠道癌症。

Sui Ziye Ph.D., Executive Director and Chief Executive Officer of Lepu Biopharma said, “We are very pleased to be working with ArriVent. Lepu Biopharma has been dedicated to promoting the technological advancement of innovative ADCs in China. We believe MRG007 is one of our potential best-in-class ADC molecules in pre-clinical stage.

乐浦生物制药执行董事兼首席执行官隋子业博士表示：“我们很高兴与ArriVent合作。乐浦生物制药一直致力于推动中国创新ADC的技术进步。我们相信MRG007是我们在临床前阶段潜在的同类最佳ADC分子之一。

The agreement is a recognition of our self-dependent R&D capabilities. We look forward to collaborating with ArriVent to advance the development of MRG007 globally and help bring this potential promising therapy to more patients around the world.”.

该协议是对我们自主研发能力的认可。我们期待着与ArriVent合作，在全球推进MRG007的发展，并帮助将这种潜在的有希望的治疗方法带给世界各地更多的患者。”。

Bing Yao, Chairman and Chief Executive Officer of ArriVent said ,' We believe MRG007 is a potential best-in-class ADC for the treatment of GI malignancies based on preclinical and IND enabling studies. Expanding our pipeline with MRG007 furthers our mission to develop novel medicines for cancers with high unmet needs worldwide and accelerates our ADC portfolio by adding a program which plans to enter the clinic in the near-term.

ArriVent董事长兼首席执行官姚冰（Bing Yao）表示，“我们相信，基于临床前和IND研究，MRG007是治疗胃肠道恶性肿瘤的潜在最佳ADC。通过MRG007扩大我们的渠道，进一步推动了我们的使命，即为全球需求未得到满足的癌症开发新药，并通过增加一个计划在近期进入诊所的计划，加速了我们的ADC投资组合。

We look forward to collaborating with Lepu Biopharma in advancing this program globally.”.

我们期待着与Lepu Biopharma合作，在全球推进这一计划。”。

About Lepu Biopharma Co., Ltd.

关于乐普生物制药有限公司。

Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) is an innovation-driven company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. The company is dedicated to developing innovative ADCs through its advanced ADC technology platform.

乐普生物制药有限公司（股票代码：02157。HK）是一家创新驱动型公司，专注于肿瘤治疗，特别是靶向治疗和肿瘤免疫治疗，具有强大的中国基础和全球视野。该公司致力于通过其先进的ADC技术平台开发创新的ADC。

Lepu Biopharma highly values the continuing build-out of its own commercialization capabilities and is determined to pursue the goal towards strong transformation from core technology to drugs and industrialization. At present, the product pipeline of Lepu Biopharma covers three major areas, namely immunotherapies, ADC targeted therapies and oncolytic virus drugs, including one clinical/commercialization- stage drug candidate, seven clinical-stage drug candidates (six of which are ADC drug candidates) and three clinical-stage combination therapies of the key candidates in its pipeline.

Lepu Biopharma高度重视自身商业化能力的持续建设，并决心追求从核心技术到药物和工业化的强大转型目标。目前，Lepu Biopharma的产品线涵盖三个主要领域，即免疫疗法，ADC靶向疗法和溶瘤病毒药物，包括一种临床/商业化阶段候选药物，七种临床阶段候选药物（其中六种是ADC候选药物）和其管道中关键候选药物的三种临床阶段联合疗法。

The company houses the leading ADC drug candidate pipeline in China..

该公司拥有中国领先的ADC候选药物管道。。

About ArriVent

关于到达

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization..

ArriVent是一家临床阶段的生物制药公司，致力于鉴别、开发和商业化分化药物，以解决癌症患者未满足的医疗需求。ArriVent寻求利用其团队深厚的药物开发经验，最大限度地发挥其领先开发候选人firmonertinib的潜力，并通过批准和商业化，推进新一代抗体-药物偶联物等新型治疗药物的管道。。

Media Contacts

媒体联系人

Lepu Biopharma Co., Ltd.

乐宝生物制药有限公司

Tel：021-6768 0899

电话：021-6768 0899

Email：pr@lepubiopharma.com

电子邮件：pr@lepubiopharma.com

Source: lepubiopharma.co

来源：lepubiopharma.co